Oncología de precisión
Un paciente, una enfermedad, un tratamiento
DOI:
https://doi.org/10.18270/rsb.v12i1.4172Palabras clave:
oncologiaResumen
no aplica
Descargas
Referencias bibliográficas
National Cancer Institute. NCI and the Precision Medicine Initiative. Precision Medicine Initiative for Oncology : Presentation to NCAB and BSA. 2017.
The Lancet. 20 years of precision medicine in oncology. Vol. 397, The Lancet. Elsevier B.V.; 2021. p. 1781.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mcguire WL. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2lneu Oncogene [Internet]. Available from: http://science.sciencemag.org/
Guy CT, Webster MA, Schallert M, Parsonst TJ, Cardifft RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Vol. 89, Genetics. 1992.
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. Vol. 17, Journal of Clinical Oncology. 1999.
Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TML. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. Journal of Clinical Oncology. 2016 Aug 20;34(24):2851–7.
Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. 2008;
Caspersson T, Gahrton G, Zech L. Identification of the Philadelphia chromosome as a number 22 by quinacrine mustard fluorescence analysis. Exp Cell Res. 1970;63(1):238–40.
Goldman JM. Chronic Myeloid Leukemia: A Historical Perspective. Semin Hematol. 2010 Oct;47(4):302–11.
Brown N, Aisner D, Oxnard G. Precision Medicine in Non–Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation. American Society of Clinical Oncology - Educational Book. 2018;38:123–35.
Politi K, Herbst RS. Lung cancer in the era of precision medicine. Clinical Cancer Research. 2015 May 15;21(10):2213–20.
Doroshow DB, Doroshow JH. Genomics and the History of Precision Oncology. Vol. 29, Surgical Oncology Clinics of North America. W.B. Saunders; 2020. p. 35–49.
Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. Vol. 4, Translational Lung Cancer Research. AME Publishing Company; 2015. p. 36–54.
Shabani Azim F, Houri H, Ghalavand Z, Nikmanesh B. Next Generation Sequencing in Clinical Oncology: Applications, Challenges and Promises: A Review Article [Internet]. Vol. 47, Iran J Public Health. 2018. Available from: http://ijph.tums.ac.ir
Mardis ER. The impact of next-generation sequencing on cancer genomics: From discovery to clinic. Cold Spring Harb Perspect Biol. 2019 Sep 1;11(9).
Cescon DW, Bratman S v., Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Vol. 1, Nature cancer. NLM (Medline); 2020. p. 276–90.
Zhong X, Zhang H, Zhu Y, Liang Y, Yuan Z, Li J, et al. Circulating tumor cells in cancer patients: Developments and clinical applications for immunotherapy. Vol. 19, Molecular Cancer. BioMed Central Ltd.; 2020.
Heidrich I, Ačkar L, Mossahebi Mohammadi P, Pantel K. Liquid biopsies: Potential and challenges. Vol. 148, International Journal of Cancer. Wiley-Liss Inc.; 2021. p. 528–45.
Sager M, Yeat NC, Pajaro-Van Der Stadt S, Lin C, Ren Q, Lin J. Transcriptomics in cancer diagnostics: Developments in technology, clinical research and commercialization. Vol. 15, Expert Review of Molecular Diagnostics. Taylor and Francis Ltd; 2015. p. 1589–603.
Rodriguez H, Zenklusen JC, Staudt LM, Doroshow JH, Lowy DR. The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment. Vol. 184, Cell. Elsevier B.V.; 2021. p. 1661–70.
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer [Internet]. Vol. 10, Am J Cancer Res. 2020. Available from: www.ajcr.us/
Liu J, Chen Z, Li Y, Zhao W, Wu JB, Zhang Z. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Vol. 12, Frontiers in Pharmacology. Frontiers Media S.A.; 2021.
Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Vol. 86, Cancer Treatment Reviews. W.B. Saunders Ltd; 2020.
Fabrizio VA, Curran KJ. Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia. Vol. 34, Best Practice and Research: Clinical Haematology. Bailliere Tindall Ltd; 2021.
Sheykhhasan M, Manoochehri H, Dama P. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. Cancer Gene Therapy. Springer Nature; 2022.
Chen L, Xu B, Long X, Gu J, Lou Y, Wang D, et al. CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome. J Immunother Cancer. 2020 Apr 28;8(1).
Shafer P, Kelly LM, Hoyos V. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects. Vol. 13, Frontiers in Immunology. Frontiers Media S.A.; 2022.
Du N, Guo F, Wang Y, Cui J. Nk cell therapy: A rising star in cancer treatment. Cancers (Basel). 2021 Aug 2;13(16).
Park JJH, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin. 2020 Mar;70(2):125–37.
Qin BD, Jiao XD, Liu K, Wu Y, He X, Liu J, et al. Basket trials for intractable cancer. Vol. 9, Frontiers in Oncology. Frontiers Media S.A.; 2019.
Prasad V, Fojo T, Brada M. Precision oncology: Origins, optimism, and potential. Vol. 17, The Lancet Oncology. Lancet Publishing Group; 2016. p. e81–6.
Sánchez NS, Mills GB, Shaw KRM. Precision oncology: Neither a silver bullet nor a dream. Vol. 18, Pharmacogenomics. Future Medicine Ltd.; 2017. p. 1525–39.
Li X, Warner JL. A Review of Precision Oncology Knowledgebases for Determining the Clinical Actionability of Genetic Variants. Vol. 8, Frontiers in Cell and Developmental Biology. Frontiers Media S.A.; 2020.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2022 Universidad El Bosque
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
El (Los) autor(es) certifican que es(son) el (los) autor(es) originario(s) del trabajo que se esta presentando para posible publicación en la Revista Salud Bosque de la Facultad Escuela Colombiana de Medicina de la Universidad El Bosque, puesto que sus contenidos son producto de su directa contribución intelectual.
Todos los datos y las referencias a materiales ya publicados deben estar debidamente identificados con su respectivo crédito e incluidos en las notas bibliográficas y en las citas que se destacan como tal y, en los casos que así lo requieran, deben contar con las debidas autorizaciones de quienes poseen los derechos patrimoniales.
El (Los) autor(es) declara(n) que todos los materiales que se presentan están totalmente libres de derecho de autor y, por lo tanto, se hace(n) responsable(s) de cualquier litigio o reclamación relacionada con derechos de propiedad intelectual, exonerando de responsabilidad a la Universidad El Bosque
